A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence

Sponsor

Roswell Park Cancer Institute (Other)

Overall Status

Recruiting

CT.gov ID

NCT04298606

Collaborator

(none)

Enrollment

Location

Arm

16.9

Anticipated Duration (Months)

3.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This early phase I trial studies the side effects of a vaccine called CIMAvax-EGF and to see how well it works in preventing lung cancer from developing in patients at high risk for lung cancer or coming back (recurrence) in stage IB-IIIA non-small cell lung cancer survivors. In many cancers such as lung cancer, there is a protein receptor called EGFR (epidermal growth factor receptor) that is overexpressed within these cancers. Activation of EGFR has shown to lead to tumor growth and development. Previous studies have indicated that EGFR activation is present in the airways of cancer-free subjects as well. CIMAvax-EGF vaccine works by causing the body to make antibodies against EGF that is being produced that could be possibly driving the risk for developing cancer.

Condition or Disease	Intervention/Treatment	Phase
Chronic Obstructive Pulmonary Disease Lung Non-Small Cell Carcinoma Pneumonia Stage IB Lung Cancer AJCC v8 Stage II Lung Cancer AJCC v8 Stage IIA Lung Cancer AJCC v8 Stage IIB Lung Cancer AJCC v8 Stage IIIA Lung Cancer AJCC v8	Other: Quality-of-Life Assessment Other: Questionnaire Administration Biological: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine	Early Phase 1

Detailed Description

PRIMARY OBJECTIVES:

To determine the efficacy of the vaccine based on circulating EGF and anti-EGF antibodies.
To access the molecular profile of blood, bronchial and nasal brushes, and bronchial biopsies to identify molecular markers associated with treatment and response.
To establish the safety of recombinant human EGF-rP64K/montanide ISA 51 vaccine (CIMAvax-EGF) treatment in cancer-free individuals using the Cancer Therapy Evaluation Program (CTEP) National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE version 5).

SECONDARY OBJECTIVE:

To evaluate quality of life score changes using European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Core 30 (C30) in patients who are at high risk for development of lung cancer or recurrence during CIMAvax-EGF treatment.

OUTLINE:

LOADING PHASE: Patients receive recombinant human EGF-rP64K/montanide ISA 51 vaccine intramuscularly (IM) at 0, 2, 4 and 6 weeks in the absence of disease progression or unacceptable toxicity.

MAINTENANCE PHASE: Patients receive recombinant human EGF-rP64K/montanide ISA 51 vaccine IM once every 4 weeks (Q4W) in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 60 days.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

60 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Prevention

Official Title:

A Phase 0 Study of CIMAvax-EGF Vaccine in Patients Who Are at High Risk for Lung Cancer and Lung Cancer Survivors at Risk for Recurrence

Actual Study Start Date :

Nov 22, 2021

Anticipated Primary Completion Date :

Apr 19, 2023

Anticipated Study Completion Date :

Apr 19, 2023

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Prevention (recombinant human EGF-rP64K/montanide ISA 51) LOADING PHASE: Patients receive recombinant human EGF-rP64K/montanide ISA 51 vaccine IM at 0, 2, 4 and 6 weeks in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive recombinant human EGF-rP64K/montanide ISA 51 vaccine IM Q4W in the absence of disease progression or unacceptable toxicity.	Other: Quality-of-Life Assessment Ancillary studies Other Names: Quality of Life Assessment Other: Questionnaire Administration Ancillary studies Biological: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine Given IM Other Names: Center of Molecular Immunology (CIMA) Epidermal Growth Factor (EGF) Vaccine Center of Molecular Immunology Epidermal Growth Factor Vaccine CimaVax CIMAvax EGF CIMAvax Epidermal Growth Factor Vaccine CimaVax Vaccine CIMAvax-EGF Recombinant Human EGF-P64K/Montanide Vaccine

Arm

Intervention/Treatment

Experimental: Prevention (recombinant human EGF-rP64K/montanide ISA 51)

LOADING PHASE: Patients receive recombinant human EGF-rP64K/montanide ISA 51 vaccine IM at 0, 2, 4 and 6 weeks in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive recombinant human EGF-rP64K/montanide ISA 51 vaccine IM Q4W in the absence of disease progression or unacceptable toxicity.

Other: Quality-of-Life Assessment

Ancillary studies

Other Names:

Quality of Life Assessment

Other: Questionnaire Administration

Ancillary studies

Biological: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine

Given IM

Other Names:

Center of Molecular Immunology (CIMA) Epidermal Growth Factor (EGF) Vaccine

Center of Molecular Immunology Epidermal Growth Factor Vaccine

CimaVax

CIMAvax EGF

CIMAvax Epidermal Growth Factor Vaccine

CimaVax Vaccine

CIMAvax-EGF

Recombinant Human EGF-P64K/Montanide Vaccine

Outcome Measures

Primary Outcome Measures

Percentage of participants with antibody titers >= 1:4000 in response to vaccination [Up to 60 days post treatment]
The response to the vaccine will be measured using circulating EGF and anti-EGF antibodies replicating the results from the Cuban and Roswell trials. Human EGF will be determined by the Roswell Park Flow and Image Cytometry CCSG supported Resource using a commercial enzyme-linked immunosorbent assay (ELISA) assay (R&D Systems, Minneapolis, MN). EGF antibodies will also be determined, by the Roswell Park Flow and Image Cytometry Resource using an in-house assay developed in cooperation with the Centro de Immunologia Molecular in La Habana, Cuba.
Molecular biomarker analysis [Up to 60 days post treatment]
Will access the molecular profile of blood, bronchial brushes, and bronchial biopsies to identify molecular markers associated with treatment and response. Biomarker scores will be analyzed for the molecular profile endpoint to test if they are significantly different post-treatment compared to pre-treatment (via paired t-test) or if a change in biomarker score (post-versus pre-) is significantly different among responders versus nonresponders (via t-test) as defined by histology and circulating levels of EGF ligand and anti-EGF antibodies. In addition to these biomarkers, gene expression signatures will be analyzed. These include gene expression signatures associated with EGFR activity, the high-grade lesion molecular subtype, and the immune-associated signature predictive of progressive/stable lesions compared with regressive lesions.
Number of patients with grade 3, 4 or 5 toxicities that are attributable to recombinant human EGF-rP64K/montanide ISA 51 vaccine (CIMAvax) [Up to 60 days post treatment]
Measured according to Cancer Therapy Evaluation Program (CTEP) National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5. The plausible range for the true (unobserved) event rate will be estimated by the upper one-sided, 95% Jeffrey's interval.

Secondary Outcome Measures

Change in quality of life scores [Baseline up to 12 months]
Will be assessed using European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Core 30 (C30).

Eligibility Criteria

Criteria

Ages Eligible for Study:

50 Years to 79 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Confirmed no evidence of cancer on computed tomography (CT) scan within 6 months prior to starting treatment
Have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2
Patients must have platelets >= 100 x 10^9/L
Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry
Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
PATIENTS AT HIGH-RISK FOR LUNG CANCER COHORT ONLY (COHORT A)
Must have documented at least one risk factor for lung cancer which includes:
Moderate to severe chronic obstructive pulmonary disease (COPD) defined as FEV1/FVC ratio <=75%
Positive family history of lung cancer defined as a first degree relative
Low body mass index (BMI)
History of pneumonia within the last 5 years prior to enrollment
Occupational exposure such as asbestos, radon and any other that investigator would deem high risk
Must have quit smoking =< 15 years ago or be a current smoker
Must have at least 30 pack year smoking history
Must have documented pulmonary function test within the last 3 years prior to enrollment. If a patient cannot tolerate a pulmonary function test, an incentive spirometry will be acceptable in place of a pulmonary function test
LUNG CANCER SURVIVOR COHORT ONLY (COHORT B)
1. If patient received surgery or any adjuvant therapy for initial diagnosis of lung cancer, it must have been completed at least 3 months prior to enrollment. Prior surgery or any therapy is not required for eligibility
Confirmed non-small cell lung cancer (NSCLC) stage IA through 3A at initial diagnosis

Exclusion Criteria:

Clinically inappropriate to have a bronchoscopy procedure
Known uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, history of clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Pregnant or nursing female participants
Unwilling or unable to follow protocol requirements
Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug
Received an investigational agent within 30 days prior to enrollment
Has known immunosuppressive disease (e.g. human immunodeficiency virus [HIV], acquired immunodeficiency syndrome [AIDS] or other immune depressing disease). Testing is not mandatory
Patient has known hypersensitivity to the components of the study drugs or any analogs
History of autoimmune disorder, with exception of patients with vitiligo or endocrine-related autoimmune conditions receiving appropriate hormonal supplementation who are eligible. Systemic use of immunosuppressant drugs such as steroids (except as hormone replacement therapy or short-course supportive medication such as chemotherapy or drug allergy, etc.), azathioprine, tacrolimus, cyclosporine, etc. within 4 weeks before recruitment
The following special populations are excluded from this study:
Cognitively impaired adults/adults with impaired decision-making capacity
Individuals who are not yet adults (infants, children, teenagers)
Prisoners
Pregnant women